King Tigan 300 Mg Promos Planned After FDA Trimethobenzamide Notice
Executive Summary
King Pharmaceuticals plans to begin promoting Tigan 300 mg for the treatment of gastroenteritis after remaining trimethobenzamide products are withdrawn from the market